Loading…
A bill to amend the Internal Revenue Code of 1986 to make permanent the reduced recognition period for built-in gains for S corporations.
Legislative Progress
Introduced
December 18, 2013
Latest Action
December 18, 2013
Primary Sponsor
Benjamin L. CardinDemocratic(MD)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 3,002 other S bills in the 113th — cohort avg 39d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (4)
2014 · first_quarter · Medical/Disease Research/Clinical Labs
BioShield Project; Biomedical Countermeasures; Biodefense Research and Development Authority; Pandemic and All-Hazards Preparedness Reauthorization (H.R. 2405 and S. 1855)
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
2013 · second_quarter · Medical/Disease Research/Clinical Labs
BioShield Project; Biomedical Countermeasures; Biodefense Research and Development Authority; Pandemic and All-Hazards Preparedness Reauthorization (H.R. 2405 and S. 1855).
Client expense: Not reported · Firm income: $40,000
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
2013 · fourth_quarter · Medical/Disease Research/Clinical Labs
BioShield Project; Biomedical Countermeasures; Biodefense Research and Development Authority; Pandemic and All-Hazards Preparedness Reauthorization (H.R. 2405 and S. 1855)
Client expense: Not reported · Firm income: $30,000
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
2013 · third_quarter · Medical/Disease Research/Clinical Labs
BioShield Project; Biomedical Countermeasures; Biodefense Research and Development Authority; Pandemic and All-Hazards Preparedness Reauthorization (H.R. 2405 and S. 1855)
Client expense: Not reported · Firm income: $50,000
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
2013 · second_quarter · Medical/Disease Research/Clinical Labs
BioShield Project; Biomedical Countermeasures; Biodefense Research and Development Authority; Pandemic and All-Hazards Preparedness Reauthorization (H.R. 2405 and S. 1855)
Client expense: Not reported · Firm income: $40,000
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
2013 · first_quarter · Medical/Disease Research/Clinical Labs
BioShield Project; Biomedical Countermeasures; Biodefense Research and Development Authority; Pandemic and All-Hazards Preparedness Reauthorization (H.R. 2405 and S. 1855)
Client expense: Not reported · Firm income: $30,000
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
2013 · first_quarter · Health Issues
H.R. 2405/S. 1855 - Pandemic and All-Hazards Preparedness Act Reauthorization, provisions relating to pandemic influenza vaccine developmentPrematurity Research Expansion and Education for Mothers Who Deliver Infants Early Reauthorization Act, provisions relating to patient safety study and report A bill to amend the Internal Revenue Code of 1986 to include vaccines against seasonal influenza within the definition of taxable vaccines Issues related to Medicaid coverage and reimbursement of biologics; securing the pharmaceutical distribution system through a federal traceability standard; reimbursement of vaccines and related services; implementation of H.R. 3590/Pub. L. No. 111-148, the Patient Protection and Affordable Care Act; biologics data exclusivity; clinical trial and testing issues; and, debt and deficit reduction proposals on Medicaid federal funding, Medicaid rebates, and Medicare Part D rebates. Issues related to Medicaid coverage and reimbursement of respiratory syncytial virus (RSV) prophylaxis and federal quality strategies for prevention of RSV. Proposed FY2014 Budgets Congressional and White House budgets--health care related provisions.
Client expense: $400,000 · Firm income: Not reported
2013 · first_quarter · Pharmacy
Issues related to the security and integrity of the domestic pharmaceutical distribution system. HR 2405 and S.1855 - Healthcare Supply Chain Safety - track and trace in the Prescription Drug Users Fee Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2013 · first_quarter · Pharmacy
- HR 2405 / S.1855 Healthcare Supply Chain Safety - track and trace in the Prescription Drug Users Fee Act
Client expense: $1,427,716 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Joint Chiefs of Staff, Labor, Dept of (DOL), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE